To The Moon

Back-to-school supplies and updates to your autumn wardrobe are popular things on people's shopping lists these days. Noted investor and Ark Invest CEO Cathie Wood, meanwhile, has been scooping up shares of growth stocks for her various ARK exchange-traded funds (ETFs).

While I can't say that I agree with all of Wood's stock purchases over the past few months, there are some stocks that her funds have snatched up that would seem to fit well in other growth investors' portfolios. They include Ginkgo Bioworks, Monday.com, and Trimble. Let's find out a bit more about these three Cathie Wood stocks that are worth more consideration.

1. Ginkgo Bioworks

A leader in the field of synthetic biology, or synbio, Ginkgo Bioworks specializes in providing its customers with improved molecules. Essentially, the company acts like an architect. Customers -- from a variety of industries, including food, pharmaceuticals, and cosmetics -- inform Ginkgo of their needs, and Ginkgo designs the blueprints for new and improved microbes. Often, Ginkgo will earn royalties or equity interests as a result of these partnerships, providing the company with good foresight into future cash flows.

Like many growth stocks this year, shares of Ginkgo have fallen steeply -- about 68.7% -- as investors shy away from investments that represent higher degrees of risk. However, the stock's plunge is not reflective of something inherently wrong with the company. This is something with which Wood seems to be familiar. Throughout August, the ARK Innovation ETF has purchased more than 7.34 million shares of Ginkgo Bioworks.

The company doesn't project profitability on an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) basis until 2025. In the meantime, though, investors can monitor the company's ability to launch new programs -- 60 are forecasted in 2022 -- as a positive sign that the company's offerings are in consistently high demand